February 2026
MDMA
What February 2026's 16 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 16 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
Research on MDMA in February 2026 shows mixed findings: it may reduce prosocial behavior in rats and has potential cardiac risks with chronic use, but also shows promise for PTSD treatment through neuroplastic and relational mechanisms, with some evidence of benefit for meaning in life in trauma-exposed individuals. Results are inconsistent across studies, with many being preclinical or small-scale, and the evidence is limited by a lack of large, controlled human trials and long-term safety data.
Confidence in the evidence
Low-Moderate- Evidence includes multiple preclinical rodent studies (e.g., article_ids 18894, 18914, 28525) and a systematic review (article_id 18895), but few large-scale human RCTs.
- Findings are mixed: some studies show potential therapeutic benefits (e.g., article_ids 25146, 27959), while others highlight risks (e.g., article_id 18895) or null effects (e.g., article_id 27954).
- Many studies are observational, qualitative, or theoretical (e.g., article_ids 18907, 25146), limiting causal inference and generalizability.
- Sample sizes are often small (e.g., n=22 in article_id 32860, n=807 in article_id 27959), and some studies lack blinding or control groups.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic Use and Missed Mental Health Treatment: Gender Differences in Behavioral Health Outcomes 2026 | observational | Mixed | Lifetime psychedelic use was not independently associated with lower odds of missing needed mental health treatment, but MDMA moderated the relationship between distress and missed care in women. | |
| SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment 2026 | review | Unclear | This position paper discusses SSRIs, psilocybin, and MDMA for PTSD, noting limited understanding of mechanisms and unanswered questions. | |
| metapsy-project/data-ptsd-mdmactr: Version 26.0.0 2026 | meta-analysis | Supports | This living meta-analytic dataset includes MDMA therapy vs. control comparisons for PTSD, with effect sizes at post-test and long-term follow-ups. | |
| MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst? 2026 | review | Supports | This review proposes a synergistic model where MDMA creates a 'window of emotional safety' enabling both neurobiological and relational healing in PTSD. | |
| Trends in toxicological findings and drug seizures of MDMA in New Zealand from 2010 to 2022 2026 | observational | 324 | Unclear | MDMA was frequently co-used with other drugs (85%+ cases), and average purity in seizures was 71%. |
| MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM. 2026 | other | Unclear | This is a corrigendum for a proof-of-principle study on MDMA-assisted therapy for major depressive disorder; no abstract available. | |
| The effects of acute and repeated adolescent MDMA exposure on behavior, cognition, and the monoamine neurotransmitter systems: A review of human and pre-clinical research 2026 | review | Mixed | Acute high-dose MDMA increased locomotor activity and impaired serotonin systems in rodents; repeated exposure effects were conflicting and dose-dependent. | |
| Lifetime MDMA use and associations with meaning in life in the context of childhood trauma 2026 | observational | 807 | Mixed | Lifetime MDMA use was not significantly associated with meaning in life overall, but was associated with higher meaning in life among those with childhood trauma. |
| Environmentally Friendly Expeditious One-Pot Electrochemical Synthesis of Bis-Catechol-Thioether Metabolites of Ecstasy: in vitro Neurotoxic Effects in the Rat Hippocampus 2026 | preclinical | Opposes | Bis-catechol-thioether metabolites of MDMA induced necrosis and apoptosis in rat hippocampal pyramidal neurons, suggesting potential neurotoxicity. | |
| Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease. 2026 | systematic review | Opposes | MDMA has high affinity for 5-HT2B receptors and promotes signaling linked to valvular heart disease, with in vitro and structural studies showing fibrotic changes. | |
| MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear. 2026 | preclinical | 210 | Supports | Repeated low-dose MDMA reduced anxiety-like behaviors in fear-conditioned rats, coinciding with oligodendroglial changes and myelin-related remodeling. |
| Stereoselective, sex-dependent 5-HT2A receptor modulation of cortical plasticity by MDMA in mice. 2026 | preclinical | Mixed | S(+)-MDMA enhanced dendritic spine density in male frontal cortex in a 5-HT2AR-dependent manner, but no spine remodeling was observed in females or with R(-)-MDMA. | |
| Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis. 2026 | qualitative | 21 | Supports | Interviews revealed perceived therapeutic benefits of MDMA-AP for PTSD, along with themes of expectation management, comprehensive screening, and flexible protocols. |
| The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults. 2026 | RCT | 22 | No effect | MDMA (100 mg) did not significantly alter plasma anandamide or 2-AG concentrations compared to placebo in healthy adults. |
| The 3,4-methylenedioxymethamphetamine (MDMA) reduces prosocial behavior in the social preference test in male and female rats. 2026 | preclinical | Opposes | MDMA reduced prosocial behavior in male rats regardless of housing, and in individually housed female rats, contrary to expectations. | |
| Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance. 2026 | review | Unclear | This review discusses placebo effects in depression treatment trials, noting implications for psychedelic-like compounds including MDMA. |
Lifetime psychedelic use was not independently associated with lower odds of missing needed mental health treatment, but MDMA moderated the relationship between distress and missed care in women.
observational
This position paper discusses SSRIs, psilocybin, and MDMA for PTSD, noting limited understanding of mechanisms and unanswered questions.
review
This living meta-analytic dataset includes MDMA therapy vs. control comparisons for PTSD, with effect sizes at post-test and long-term follow-ups.
meta-analysis
This review proposes a synergistic model where MDMA creates a 'window of emotional safety' enabling both neurobiological and relational healing in PTSD.
review
MDMA was frequently co-used with other drugs (85%+ cases), and average purity in seizures was 71%.
observational Sample size: 324
This is a corrigendum for a proof-of-principle study on MDMA-assisted therapy for major depressive disorder; no abstract available.
other
Acute high-dose MDMA increased locomotor activity and impaired serotonin systems in rodents; repeated exposure effects were conflicting and dose-dependent.
review
Lifetime MDMA use was not significantly associated with meaning in life overall, but was associated with higher meaning in life among those with childhood trauma.
observational Sample size: 807
Bis-catechol-thioether metabolites of MDMA induced necrosis and apoptosis in rat hippocampal pyramidal neurons, suggesting potential neurotoxicity.
preclinical
MDMA has high affinity for 5-HT2B receptors and promotes signaling linked to valvular heart disease, with in vitro and structural studies showing fibrotic changes.
systematic review
Repeated low-dose MDMA reduced anxiety-like behaviors in fear-conditioned rats, coinciding with oligodendroglial changes and myelin-related remodeling.
preclinical Sample size: 210
S(+)-MDMA enhanced dendritic spine density in male frontal cortex in a 5-HT2AR-dependent manner, but no spine remodeling was observed in females or with R(-)-MDMA.
preclinical
Interviews revealed perceived therapeutic benefits of MDMA-AP for PTSD, along with themes of expectation management, comprehensive screening, and flexible protocols.
qualitative Sample size: 21
MDMA (100 mg) did not significantly alter plasma anandamide or 2-AG concentrations compared to placebo in healthy adults.
RCT Sample size: 22
MDMA reduced prosocial behavior in male rats regardless of housing, and in individually housed female rats, contrary to expectations.
preclinical
This review discusses placebo effects in depression treatment trials, noting implications for psychedelic-like compounds including MDMA.
review
Points of agreement
- Multiple studies (e.g., article_ids 25146, 18894, 18907) suggest MDMA-assisted therapy shows promise for PTSD, with potential mechanisms involving neuroplasticity and therapeutic alliance.
- Preclinical studies (e.g., article_ids 18894, 18914) indicate MDMA affects serotonin systems and neural plasticity, though effects are sex- and dose-dependent.
- Observational studies (e.g., article_ids 27954, 27959) find that MDMA use may buffer against negative outcomes in specific populations (e.g., those with trauma).
Conflicts
- Article_id 28525 found MDMA reduced prosocial behavior in rats, contradicting the common assumption that MDMA enhances prosociality.
- Article_id 27954 found no independent association between psychedelic use and reduced missed mental health treatment, while article_id 27959 found MDMA associated with higher meaning in life in trauma-exposed individuals.
- Article_id 18895 highlights cardiac risks from chronic MDMA use, while article_ids 25146 and 18907 emphasize therapeutic benefits, reflecting a risk-benefit tension.
Gaps
- Lack of large-scale, long-term human RCTs on MDMA-assisted therapy for PTSD and other conditions.
- Limited data on MDMA effects in adolescents (article_id 25122) and females (article_ids 18914, 25122).
- Durability of therapeutic effects and safety of repeated dosing are not well-studied.
- Mechanisms of action (e.g., neuroplastic vs. relational) remain debated and incompletely understood (article_ids 25146, 24901).